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Abstract
Introduction Methicillin-resistant Staphylococcus aureus
(MRSA) causes severe morbidity and mortality in intensive care
units (ICUs) worldwide. The purpose of this study was to
determine whether intranasal mupirocin prophylaxis is useful to
prevent ICU-acquired infections with MRSA.
Materials and methods We conducted a 4-year observational
retrospective study in a 15-bed adult medical ICU. During the
first 2-year period mupirocin ointment was included in the
MRSA control programme; during the second, mupirocin was
not used. The main endpoint was the number of endogenous
ICU-acquired infections with MRSA.
Results The number of endogenous acquired infections was
significantly higher during the second period than during the first
(11 versus 1; P  = 0.02), although there was no significant
difference in the total number of patients infected with MRSA
between the two periods. We also observed that nasal MRSA
decolonisation was significantly higher in the mupirocin period
than in mupirocin-free period (P = 0.002).
Conclusion Our findings suggest that intranasal mupirocin can
prevent endogenous acquired MRSA infection in an ICU.
Further double-blind, randomised, placebo-controlled studies
are needed to demonstrate its cost-effectiveness and its impact
on resistance.
Introduction
Over the past four decades, methicillin-resistant Staphylococ-
cus aureus (MRSA) has spread throughout the world and
become highly endemic in many geographic areas. This path-
ogen causes severe morbidity and mortality in hospitals world-
wide [1-3]. In France, 30 to 40% of S. aureus strains are
methicillin-resistant and the median incidence of MRSA in clin-
ical specimens is about 0.8 per 1000 patient-days in acute
care facilities and 3.42 in intensive care units (ICUs) [4].
French intensive care experts had recommended that barrier
precautions should be implemented for patients colonised or
infected with MRSA, but there is no consensus about an
MRSA screening programme and MRSA nasal decolonisa-
tion. Systematic MRSA screening on admission and preven-
tive isolation have been shown to be cost-effective [5-7] but
the usefulness of mupirocin-based nasal decolonisation
remains a matter of debate. Indeed, mupirocin has emerged as
the topical antibacterial agent of choice for the elimination of
S. aureus nasal carriage. In hospitals in which MRSA is epi-
demic, the intra-nasal administration of mupirocin to both
patients and personnel colonised with MRSA is considered to
be appropriate [8]. Furthermore, mupirocin has been used
successfully to prevent staphylococcal infections in surgical
and haemodialysis patients [9]. Although the available litera-
ture does not support routine use of intranasal mupirocin to
prevent subsequent infections, there may be a role in some
selected cases, such as those involving critically ill patients
[9]. Thus, it was reported that intranasal mupirocin could
decrease the occurrence of S. aureus pneumonia in ICU
patients [10]. In 1994, an MRSA control programme was
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implemented in all high-risk units of our hospital, including
adult ICUs. Thus, all patients were screened for MRSA on
admission and during hospitalisation; MRSA-positive patients
were kept in isolation and positive patients were prescribed
nasal mupirocin ointment. In June 2001, clinicians from the
medical ICU decided to stop using mupirocin for MRSA nasal
decolonisation. We conducted a retrospective study to deter-
mine whether intranasal mupirocin prophylaxis is useful in pre-
venting ICU-acquired infections with MRSA.
Materials and methods
Setting and study period
The 15-bed medical ICU of Besançon hospital admits about
450 to 500 patients per year, giving a mean of 5,000 patient-
days per year. All patients admitted between 1 June 1999 and
31 May 2003 were included in this retrospective study. Mean
ICU length of stay, mean gravity scores (Simplified Acute
Physiology Score, SAPSII) and fatality rates were calculated
monthly [11]. Ethical approval for this study was granted by
the ethical committee of the hospital.
MRSA control programme
The MRSA control strategy was based on screening nasal
fluid samples from all patients for MRSA on admission and
once a week during hospitalisation. When the screening test
was positive for MRSA, patients were given nasal mupirocin
for 5 days, even if other body sites were colonised with MRSA.
Special precautions were taken to prevent cross-contamina-
tion, including the use of disposable gowns and gloves, the
use of an alcohol rub for hand hygiene, and the implementation
of strict environmental hygiene measures. The MRSA status of
the patient was written on the door of their room and in their
medical chart. The patient was removed from isolation when
two consecutive screening tests were negative and no clinical
samples tested positive for MRSA. The programme did not
include restrictions on antibiotic use. This programme was
applied in our medical ICU until June 2001. At that date, nasal
mupirocin ointment was stopped.
Microbiological techniques
The screening programme involved the collection of nasal
samples from each patient and of tracheal aspirates from ven-
tilated patients. Clinical diagnostic samples were obtained as
requested by the physician in charge of the patient. Screening
samples were used to inoculate both Mueller–Hinton agar and
Mueller–Hinton agar supplemented with 10 mg/l tobramycin
because 20% of all MRSA isolated in our hospital are
tobramycin-susceptible [12,13]. Plates were examined for sta-
phylococci after 24 hours at 37°C. Identification of S. aureus
was initially based on colony aspect and the detection of both
clumping factor and protein A with the Pastorex Staph-Plus
latex agglutination test (Bio-Rad, Marnes la Coquette, France).
Complementary tests, such as the coagulase and DNase
tests, were performed if necessary. S. aureus strains that grew
both on plates with and on those without tobramycin were
considered to be MRSA. Indeed, a continuous surveillance of
antimicrobial resistance among clinical samples showed that
more than 98% of methicillin-susceptible Staphylococcus
aureus were susceptible to tobramycin. Those that grew only
on tobramycin-free plates were tested for oxacillin resistance.
This antibiotic susceptibility was determined with the disk dif-
fusion technique by incubating with 5 µg oxacillin disks for 48
hours at 30°C, as recommended by the Antibiogram Commit-
tee of the French Society for Microbiology [14]. S. aureus
strains with oxacillin inhibition zones of less than 20 mm (cor-
responding to a minimum inhibitory concentration of more than
2 mg/l) were classified as MRSA. About 75% of the positive
MRSA screening results were obtained within 24 hours; the
others (25%) were obtained within 48 hours.
MRSA definitions
The following definitions were used: case, a patient from
whom MRSA was recovered from any site irrespective of the
sample type (screening or clinical); carrier, a patient from
whom MRSA was recovered from screening samples or from
clinical samples without signs of infection; and infected
patient, a patient from whom MRSA was recovered from clini-
cal samples with signs of infection according to the definitions
of the Centers for Disease Control and Prevention [15]. MRSA
was considered to be imported if the patients tested positive
within 48 hours of admission in the ICU and to be acquired
MRSA if they tested negative for the first 48 hours after admis-
sion. Infections were considered to be endogenous if a
screening sample was positive before the clinical sample, or
exogenous otherwise. MRSA was considered to have been
eradicated when two consecutive screening tests were
negative.
Antibiotic use
The quantities of each antimicrobial delivered to the ICU were
determined from the pharmacy information system. Grams and
international units of antimicrobials were further converted into
defined daily doses (DDD) in accordance with the recommen-
dations of the World Health Organization [16]. The amount of
each class of antibiotics used is expressed in DDD per 1,000
days of hospitalisation.
Statistical analysis
The aim of the study was to compare ICU-acquired infections
with MRSA before (period 1, June 1999 to May 2001) and
after (period 2, June 2001 to May 2003) the use of intranasal
mupirocin stopped. Analysis was performed by using the χ 2
test and Fisher's exact test for categorical variables and the
Mann–Whitney test for continuous variables. P ≤  0.05 was
considered to be significant. Statistical analysis was per-
formed with Epi-info 6.0 (Centers for Disease Control and Pre-
vention, Atlanta, GA) and R (The R Project for Statistical
Computing, http://www.r-project.org) software.Available online http://ccforum.com/content/9/3/R246
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Results
During the first study period with mupirocin use, 912 patients
were admitted to the medical ICU, 775 were screened for
MRSA (84.5%), 38 were MRSA carriers and 9 were infected
with MRSA. During the second period without mupirocin use,
987 patients were admitted, 819 were screened (83.0%), 49
were MRSA carriers and 17 were infected with MRSA (Table
1). The number of endogenous acquired infections was signif-
icantly higher during the second period than during the first
(11 versus 1; P = 0.006, relative risk = 8.53 (CI95% [1.15–
63.21])) although there was no significant difference in the
total number of patients infected with MRSA between the two
periods. The 12 endogenous acquired infections detected are
described in Table 2. In the second period, the delay between
the detection of MRSA carriage and the date of the first posi-
tive clinical sample was sufficient to implement nasal mupi-
rocin ointment for 7 of the 11 infected patients. Three patients
died during the 2 weeks after the MRSA bacteraemia or
pneumonia.
We next evaluated the efficiency of nasal mupirocin for MRSA
eradication. The rate of nasal MRSA decolonisation among the
patients hospitalised for more than 14 days after the discovery
of MRSA carriage (delay necessary to evaluate the efficacy of
mupirocin) reached 86.4% in period 1 and just 46.4% in
period 2 (P = 0.002). Three of the 19 patients who were suc-
cessfully decolonised during the first period received concom-
itant treatment with antimicrobials effective against MRSA
(namely vancomycin).
The total amount of antibiotics used remained stable during
the study period (1,700 DDD per 1,000 hospitalisation days)
and the use of glycopeptides did not significantly vary (104
DDD per 1,000 hospitalisation days in the first period and 91
in the second period).
Discussion
Our observational study suggests that nasal mupirocin can
effectively prevent the occurrence of endogenous acquired
MRSA infections in ICUs. The increase in endogenous ICU-
acquired MRSA infections in the second period occurred
although different indicators such as mean length of stay,
mean gravity scores of fatality rates did not significantly vary
between the periods (Table 1). In 7 of the 11 MRSA infections
observed in the period 2, the delay between the two samples
was sufficient to implement mupirocin treatment; that is, at
least 5 days. Our findings stand in contrast to double-blind
randomised, placebo-controlled trials that included patients
hospitalised in different type of unit [17]. However, in this
study, the number of infections was three in the mupirocin
group and seven in the placebo group. It is likely that the enrol-
ment of more than 98 patients would show a significant effect
of mupirocin in preventing subsequent MRSA infection. More-
over, the only randomised study applied to ICU patients also
concluded that mupirocin was effective in reducing the occur-
rence of S. aureus pneumonia [10].
Some limitations of our study have to be addressed. First, we
compared historical groups, whereas randomised, double-
blind placebo controlled trials are more powerful. However,
Table 1
Description of the medical intensive care unit of Besançon hospital, June 1999 to May 2003
Parameter Period 1 (June 1999 to May 2001) Period 2 (June 2001 to May 2003) P
No. of patients admitted 912 987
Patients screened for MRSA (% of 
patients admitted)
775 (84.5%) 819 (83.0%) 0.26
Mean length of stay, days 11.44 9.73 0.02
Mean gravity score, SAPS II 46.32 46.44 0.91
Rate of death, % 32.73 28.43 0.07
MRSA cases 46 55 0.59e
Carriers of MRSAa (then infected) 38 (1) 49 (11) 0.35g
Infected with MRSAb 91 7 0 . 2 4 e
Imported MRSAc 6 4 0.66e
Exogenous acquired MRSAc,d 2 2 1.00f
Endogenous acquired MRSAc,d 11 1 0.006g
aPatients from whom methicillin-resistant Staphylococcus aureus (MRSA) was recovered from screening samples or from clinical samples without 
signs of infection. bPatients from whom MRSA was recovered from clinical samples with signs of infection in accordance with the definitions of the 
Centers for Disease Control and Prevention. cDefined as imported if they tested positive within 48 hours of admission, and as acquired if they 
tested negative for the first 48 hours after admission. dDefined as endogenous if a screening sample was positive before the clinical sample, and 
as exogenous otherwise. eIn comparison with admitted patients. fIn comparison with screened patients. gIn comparison with carriers of MRSA. 
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MRSA infection remains a rare event in our medical ICU and a
very large study period would be needed to show that a pro-
gramme including mupirocin use is beneficial. We simply
reported the evolution of the infections with MRSA between
two periods during which only one element had changed: the
use of mupirocin for nasal MRSA decolonisation.
Second, we have not evaluated mupirocin resistance in this
study. Low-level mupirocin resistance has been identified as a
risk factor for a failure to eradicate MRSA [18], and numerous
authors have reported the emergence of mupirocin resistance
in settings where mupirocin is commonly used [19]. Concerns
over the development of resistance have dissuaded many hos-
pitals from using mupirocin in this manner, and recent recom-
mendations from the guidelines of the Society for Healthcare
Epidemiology of America stated that 'widespread use, pro-
longed use or both of decolonization therapy should be
avoided' [20]. Others studies have reported that relapse of
MRSA carriage was not associated with the development of
resistance to mupirocin [21,22].
The body of the literature currently does not support routine
intranasal mupirocin prophylaxis to all inpatients to decrease
the rate of clinical infection. However, there might be as yet
unidentified patient populations that could benefit. One can
speculate that a significant effect should be seen for patients
at high risk of infection, such as patients admitted to ICUs
[23]. Indeed, our data showed that the infectious risk in our
ICUs is high; during period 2 (mupirocin-free), 25.6% of carri-
ers became infected (Table 1). A recent meta-analysis
reported a significant increase in mortality associated with
MRSA infection (odds ratio 1.93) and most studies depicted
a crude mortality rate between 20% and 40% [3].
Our results concerning MRSA nasal eradication are in agree-
ment with those observed by several authors in different set-
tings, Kalmeijer and colleagues reported that MRSA was
eradicated from 83.5% of patients admitted for orthopaedic
surgery [24], and Mody and colleagues also showed that treat-
ment with mupirocin had decolonised 93% of residents in
long-term care facilities [21]. However, they differed from
those obtained in other randomised trials. This difference was
probably due to the status of the patients included, regardless
of the type of setting.
Conclusion
Our results suggest that the use of mupirocin to prevent
MRSA infections in ICUs has to be evaluated. Further double-
blind, randomised, placebo-controlled clinical trials are
needed to demonstrate its cost-effectiveness and its impact
on mupirocin resistance.
Table 2
Characteristics of endogenous invasive MRSA infections
Patient no. Type of 
infection
Period Date of 
infection
Delay between 
admission and 
infection (days)
Delay between positive 
MRSA screening and 
infection (days)
Antibiotic 
treatment (Y/N)
Death (Y/N) Time between 
infection and 
death (days)
1 Pneumonia P1 4 Sep 2000 26 7 Y (vancomycin) N
2 Bacteraemia P2 14 Aug 2001 8 7 Y (vancomycin) Y 15
3 Pneumonia P2 29 Aug 2001 37 6 Y (vancomycin) N
4 Pneumonia P2 29 Aug 2001 13 2 N Y 0
5 Endocarditis P2 10 Oct 2001 6 6 Y (vancomycin) N
6 Bacteraemia P2 24 Dec 2001 18 13 Y (vancomycin) N
7 Bacteraemia P2 16 Feb 2002 8 5 Y (vancomycin) N
8 Pneumonia P2 1 Apr 2002 3 2 Y (vancomycin) N
9 Pneumonia P2 6 Jun 2002 13 13 Y (vancomycin) N
10 Bacteraemia P2 22 Jun 2002 26 26 Y (vancomycin) N
11 Pneumonia P2 6 Feb 2003 13 3 Y (linezolid) Y 7
12 Pneumonia P2 24 Mar 2003 7 5 Y (vancomycin) N
MRSA, methicillin-resistant Staphylococcus aureus; P1, June 1999 to May 2001; P2, June 2001 to May 2003.
Key messages
•  MRSA causes severe morbidity and mortality in ICUs 
worldwide.
•  Mupirocin is regarded as the topical antibacterial agent 
of choice for the elimination of S. aureus nasal carriage.
•  The body of the literature does not currently support 
routine intranasal mupirocin prophylaxis.
•  Our observational study suggests that nasal mupirocin 
can effectively prevent the occurrence of endogenous 
acquired MRSA infections in ICUs.
• Further  double-blind,  randomised, placebo-controlled 
clinical trials are needed to confirm our findings in ICUs.Available online http://ccforum.com/content/9/3/R246
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